We have an updated report [Version - 2024] available. Kindly sign up to get the sample of the report.
all report title image

ALAGILLE SYNDROME TREATMENT MARKET ANALYSIS

Alagille Syndrome Treatment Market, By Drug (Ursodeoxycholic Acid, Cholestyramine, Rifampicin, Late Stage Pipeline Drugs, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)

  • Published In : Oct 2023
  • Code : CMI4398
  • Pages :156
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Alagille Syndrome Treatment MarketSize and Trends

The global alagille syndrome treatment market is estimated to be valued at US$ 88.9 Million in 2023 and is expected to exhibit a CAGR of 6.6% during the forecast period (2023-2030).

Figure 1. Global Alagille Syndrome Treatment Market Share (%), By Drug, 2023

Global Alagille Syndrome Treatment Market - Drivers

  • Increasing interest by researchers and key market palyers : There is an increase in interest among researchers and key market players to explore Alagille syndrome treatment options more effectively. This is primarily due to its potential to significantly improve the quality of life of patients and address unmet medical needs in this rare genetic disorder. Alagille syndrome is a complex condition that affects multiple organ systems including the liver, heart, and kidneys. As current treatment options are limited and often focused on managing symptoms, there is a growing urgency to develop innovative therapies that can target the underlying cause of the syndrome. By advancing research in this area, researchers and market players aim to provide hope for patients and their families by offering more effective and tailored treatment approaches. These therapies could potentially improve the quality of life for individuals with Alagille syndrome and reduce the need for invasive procedures such as liver transplants. Additionally, by understanding the underlying cause of the syndrome, researchers may be able to identify potential biomarkers or genetic targets that could lead to earlier diagnosis and intervention.

Global Alagille Syndrome Treatment Market Segmentation:

The global alagille syndrome treatment market report is segmented into drug, distribution channel, and region.

  • By drug, the market is segmented into ursodeoxycholic acid, cholestyramine, rifampicin, late stage pipeline drugs, and others. Out of which, ursodeoxycholic acid is expected to hold a dominant position in the global alagille syndrome treatment market during the forecast period, and this is attributed to the increasing ursodeoxycholic acid use for the development of new drugs to treat alagille syndrome.
  • By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Out of which, hospital pharmacies is expected to dominate the market over the forecast period, and this is attributed to the increasing patient pool of Alagille syndrome.
  • Among all the segmentation, the drug segment is expected to dominate the market over the forecast period, and this is explained by the rising preference of pharmaceutical raw materials for the creation of new medications to treat Alagille syndrome.  

Global Alagille Syndrome Treatment Market: Key Trends

  • Approval and launch of new drugs for the treatment: The launch of drug in more than one region for the treatment of Alagille syndrome is expected to drive the growth of the global alagille syndrome treatment market over the forecast period. For instance, in December 2022, Mirum Pharmaceuticals, Inc., a biopharmaceutical company, announced that the European Commission has granted marketing authorization for LIVMARLI (maralixibat) oral solution for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) two months of age and older. The approval follows a positive opinion granted by the European Committee for Medicinal Products for Human Use (CHMP) in September 2022. LIVMARLI is the first and only approved treatment in both the European Union and the U.S. to treat this rare liver disease affecting one out of 30,000 people globally.

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Credibility and Certifications

27001:2022

Credibility and Certifications

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.